AMG510單一構(gòu)型生物活性靶點(diǎn)體外研究體內(nèi)研究MSDS用途與合成方法AMG510單一構(gòu)型價(jià)格(試劑級(jí))上下游產(chǎn)品信息中文名稱:AMG510單一構(gòu)型中文同義詞:AMG510單一構(gòu)型;(1R)-6-氟-7-(2-氟-6-羥基苯基)-1-[4-甲基-2-(1-甲基乙基)-3-吡啶基]-4-[(2S)-2-甲基-4-(1-氧代-2-丙烯-1-基)-1-哌嗪基]-吡啶并[2,3-D]嘧啶-2(1H)-酮;索托拉西;索托拉司;SOTORASIB單一構(gòu)型;AMG510游離態(tài);索托拉西布;AMG510(索托拉西布)英文名稱:Sotorasib英文同義詞:PYRIDO[2,3-D]PYRIMIDIN-2(1H)-ONE,6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-1-[4-METHYL-2-(1-METHYLETHYL;Pyrido[2,3-d]pyrimidin-2(1H)-one,6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-,(1R)-;AMG-510(Sotorasib);6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one;Storasib;CID137278711;Pyrido[2,3-d]pyrimidin-2(1H)-one,6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-,(1R)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one;SotorasibCAS號(hào):2296729-00-3分子式:C30H30F2N6O3分子量:560.61EINECS號(hào):相關(guān)類別:抑制劑;標(biāo)準(zhǔn)品;小分子抑制劑;原料;抗腫瘤類;原料藥及中間體;科研出口類;特殊化學(xué)品;貝爾卡主打;武漢貝爾卡主打;APIMol文件:2296729-00-3.molAMG510單一構(gòu)型性質(zhì)沸點(diǎn)730.5±70.0°C(Predicted)密度1.36±0.1g/cm3(Predicted)酸度系數(shù)(pKa)6.52±0.35(Predicted)AMG510單一構(gòu)型用途與合成方法生物活性Sotorasib(AMG510)是有效的KRASG12C共價(jià)抑制劑，具有潛在的抗腫瘤活性。該AMG510是手性化合物。靶點(diǎn)TargetValueK-Ras(G12C)()體外研究AMG510抑制SOS1催化的重組突變體KRAS(G12C/C118A)的核苷酸交換，但對(duì)單突變KRAS(C118A)影響甚微。AMG510選擇性地降低含KRASp.G12C突變的細(xì)胞系生存活力，而對(duì)含其它KRAS突變的細(xì)胞系無影響。體內(nèi)研究在臨床前腫瘤模型中，AMG510可快速地以不可逆方式結(jié)合KRAS(G12C)，持久地抑制MAPK信號(hào)通路。對(duì)含KRAS(G12C)突變的小鼠腫瘤模型通過口服途徑單次給藥，AMG510能夠誘導(dǎo)腫瘤消退。安全信息MSDS信息